Compare Organon & Co. Common Stock (OGN) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Under Armour Inc Class A — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Under Armour Inc Class A trades at $4.79 (market cap $2.08B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Under Armour Inc Class A for 99 Days on average.
| OGN | UAA | |
|---|---|---|
Market Cap | $3.61B | $2.08B |
Volume | 1,808,049 | 7,012,020 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $8.14 |
52-Week Low | $5.70 | $4.17 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $11.03B | $3.06B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Under Armour (UAA) trades at $4.90, down 0.61% amid ongoing revenue challenges but shows technical bullish signals. The company reported mixed Q2 2026 results with an earnings beat but faces declining revenues and negative net margins. Recent news highlights Under Armour's strategic focus on product simplification and international growth while navigating North American weakness. Technical indicators show bullish moving averages with RSI suggesting potential overbought conditions near-term.
The outlook remains challenging with revenue declines projected through 2026, though cost discipline supports margin recovery. Investment opportunity exists if the brand transformation succeeds, but risks include persistent demand weakness and competitive pressures. Analyst consensus is mixed with a $5.79 price target representing 18% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
